John MacMahon

CONTACT

Laura A Minarsch

CONTACT

Lead Sponsor

Mitre Medical Corp.

Collaborators

Age

22 - No limit years

Sex

ALL

Healthy Volunteers

No

•Moderate or greater (2+) ischemic
•Functional Mitral regurgitation by 2D echocardiography using an integrative method
•Patient is scheduled for cardiac surgery (e.g. CABG including patients on the waiting list for Heart Transplantation)
•Patient is 22 years of age or older
•Patient is willing and able to sign Informed Consent Form
•Within 90 days patients should be on stable optimally uptitrated medical therapy recommended according to current guidelines23 as standard of care for heart failure therapy in the United States

•Any evidence of structural (chordal or leaflet) mitral valve disease
•Inability to derive ERO, LVESVI or LVEDVI by TTE
•Prior surgical or percutaneous mitral valve intervention
•Contraindication to cardiopulmonary bypass (CPB)
•Clinical signs of cardiogenic shock
•Treatment with chronic intravenous inotropic therapy
•Severe, irreversible pulmonary hypertension in the judgement of the investigator
•ST segment elevation requiring intervention within 7 days prior to randomization
•Congenital heart disease (except PFO or ASD)
•Evidence of cirrhosis or hepatic synthetic failure
•Renal insufficiency (eGFR \< 30 ml/min)
•History of endocarditis or current endocarditis
•Ejection fraction \<25%
•NY heart class IV
•MV diameters \> 7cm
•Any coronary artery calcification at site of placement as determined by angiogram
•Myxomatous mitral regurgitation
•Women who are pregnant (by history of menstrual period or pregnancy test if history is considered unreliable)
•Abnormal cardiac anatomy discovered prior to surgery or during procedure
•Pericardial adhesions
•Insufficient clinical signature reduction of mitral regurgitation during device sizing and placement. (No device remains, patient moved to only 30-Day follow-up.)